InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.050
+0.030 (2.94%)
At close: Apr 1, 2025, 4:00 PM
1.020
-0.030 (-2.86%)
After-hours: Apr 1, 2025, 4:15 PM EDT
InflaRx Revenue
In the year 2024, InflaRx had annual revenue of 165.79K EUR with 162.79% growth. InflaRx had revenue of -423.00 in the quarter ending December 31, 2024, a decrease of -118.50%.
Revenue (ttm)
165.79K EUR
Revenue Growth
+162.79%
P/S Ratio
415.51
Revenue / Employee
2,240 EUR
Employees
74
Market Cap
70.98M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IFRX News
- 12 days ago - InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 25 days ago - InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire
- 4 weeks ago - InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire
- 5 weeks ago - InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences - GlobeNewsWire
- 5 weeks ago - InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewsWire